NCT05966584终止2 期
RETENTION: An Open-Label Phase 2 Trial of InteRlEukin (5) InhibiTion for the prEveNTION of Alpelisib Rash in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 7
- 主要终点
- Proportion of Subjects That Have a Grade ≤1 Rash
研究概览
简要总结
The researcher are doing this study to find out whether benralizumab is effective at preventing skin rashes caused by alpelisib in people who have metastatic breast cancer. Skin rash is a common side effect of alpelisib. Researchers think adding benralizumab to the standard-of-care hormone treatment and alpelisib may prevent the patient from getting a rash.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed metastatic HR-positive, HER2-negative breast cancer. HR positive is defined by ER status >10% immunohistochemical (IHC) staining of any intensity.
- •Must be scheduled to receive SOC endocrine therapy (alpelisib plus fulvestrant or AIs)
- •Presence of one or more activating PIK3CA mutations in tumor tissue.
- •Measurable disease per RECIST v1.1 OR at least one predominantly lytic bone lesion must be present.
- •Written informed consent provided
- •Female or male ≥18 years of age
- •Eastern Cooperative Oncology Group performance status of 0 or
- •Life expectancy ≥6 months.
- •Adequate organ and marrow function as defined below:
- •Hemoglobin ≥8.0 g/dL (without blood transfusion within 7 days of laboratory test used to determine eligibility)
- •Absolute neutrophil count ≥1.0 × 10^9 /L (without granulocyte colony stimulating factor support within 2 weeks of laboratory test used to determine eligibility)
- •Platelet count ≥50 × 10^9 /L (without transfusion within 2 weeks of laboratory test used to determine eligibility)
- •Total bilirubin (TB) ≤1.0 × institutional upper limit of normal (ULN; Patients with known Gilbert's disease who have TB ≤3 × ULN may be enrolled)
- •Aspartate transaminase/alanine transaminase ≤2.5 × ULN with normal alkaline phosphatase (≤5 × ULN for patients with liver metastases) OR ≤1.5 × ULN in conjunction with alkaline phosphatase >2.5 × ULN
- •Creatinine ≤1.5 mg/dL
- •Able to swallow oral medication.
- •Willing to be randomized to any of the treatment arms and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
- •Women must be of postmenopausal status. Postmenopausal status is defined by any one of the following criteria:
- •Prior bilateral oophorectomy
- •Age ≥60 years
- •Age <60 years and amenorrheic for at least 12 months (spontaneous cessation of menses for 12 consecutive months or more in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression) and follicle-stimulating hormone and estradiol levels in the postmenopausal range without an alternative cause.
排除标准
- •Known hypersensitivity to alpelisib, fulvestrant or AIs, benralizumab, cetirizine, or to any of the excipients of alpelisib, fulvestrant or AIs, benralizumab, or cetirizine.
- •Concurrent malignancy (basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cervical cancer in situ that have undergone curative intent therapy are allowed)
- •Individuals with impaired decision making capacity.
- •Concurrent use of another investigational drug or device for the rash (i.e., outside of study treatment) during, or within 4 weeks of treatment.
- •Known use of anti-IL-5 agents or other biologics for the treatment of asthma which are known to decrease blood eosinophil levels within the past 12 weeks.
- •Known history of anaphylaxis to benralizumab therapy.
- •A helminthic parasitic infection diagnosed within 24 weeks prior to the first treatment, and assent when applicable, was obtained that had not been treated with, or has failed to respond to, standard of care therapy.
- •Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
- •Active infection that would impair the ability of the patient to receive study treatment.
- •Women who are pregnant or breast-feeding.
- •Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
- •Oral corticosteroids at a dose of ≥20mg/day prednisone or equivalent within 14 days expected to continue during alpelisib therapy.
- •More than 2 lines of endocrine-based therapy in the metastatic setting.
研究组 & 干预措施
Benralizumab and PI3K inhibition (alpelisib)
Experimental
Patients will receive fulvestrant or AIs and PI3K inhibition (alpelisib) per SOC (fulvestrant on days 1, 15, 29 and monthly thereafter; Ais on a daily continuous basis). Participants will receive one injection of benralizumab 30mg subcutaneously on day -1.
干预措施: Benralizumab (Drug)
Benralizumab and PI3K inhibition (alpelisib)
Experimental
Patients will receive fulvestrant or AIs and PI3K inhibition (alpelisib) per SOC (fulvestrant on days 1, 15, 29 and monthly thereafter; Ais on a daily continuous basis). Participants will receive one injection of benralizumab 30mg subcutaneously on day -1.
干预措施: fulvestrant or AIs) and PI3K inhibition (alpelisib) (Drug)
结局指标
主要结局
Proportion of Subjects That Have a Grade ≤1 Rash
时间窗: 4 weeks
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
已完成
2 期
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical CystectomyStage I Bladder Cancer AJCC v8Stage II Bladder Cancer AJCC v8Stage III Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8Stage IIIB Bladder Cancer AJCC v8NCT03319745M.D. Anderson Cancer Center23
已完成
2 期
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell LymphomaContiguous Stage II Mantle Cell LymphomaNoncontiguous Stage II Mantle Cell LymphomaStage I Mantle Cell LymphomaStage III Mantle Cell LymphomaStage IV Mantle Cell LymphomaNCT02242097Northwestern University37
已完成
2 期
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate CancerCastration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneProstate AdenocarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8NCT03204812M.D. Anderson Cancer Center31
已完成
2 期
Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-TProstate CancerNCT01174368The Rogosin Institute1
已完成
2 期
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal CancerPancreatic Adenocarcinoma Non-resectablePancreatic Adenocarcinoma MetastaticColorectal Cancer MetastaticNCT01053013The Rogosin Institute58